Clinical Trials
42 trialsNeoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study
Sun Yat-sen University
TRIUNITE-08
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
CHIMERA
Gruppo Oncologico del Nord-Ovest
ERASE-CRC
Gruppo Oncologico del Nord-Ovest
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer
First Affiliated Hospital of Guangxi Medical University
NeoCHIC
Ruijin Hospital
ACE
Oslo University Hospital
Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer(Neo-Color)
Hebei Medical University Fourth Hospital
NICER
Baylor College of Medicine
Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer
Sun Yat-sen University
REPROGRAM-01
Centre Hospitalier Universitaire de Besancon
AVANA
Gruppo Oncologico del Nord-Ovest
Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial
IFOM ETS - The AIRC Institute of Molecular Oncology
ICONIC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon
NSABP Foundation Inc
Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer
Medical Research Council
Capecitabine and Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
UNICANCER
Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
UNICANCER
SorCape
University of Florida
FluoHeart
Helsinki University Central Hospital
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
AEterna Zentaris
ADAPT
University of Washington
Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer
University of California, Davis
Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)
H. Lee Moffitt Cancer Center and Research Institute
Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
Hoffmann-La Roche
Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic
Centro Nacional de Investigaciones Oncologicas CARLOS III
Neoadjuvant Treatment of Colon Cancer
Vejle Hospital
Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer
Duke University
Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment
City of Hope Medical Center
Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer
Roswell Park Cancer Institute
NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer
AGC Biologics S.p.A.
Capecitabine and Gemcitabine in Patients With Metastatic Colorectal Cancer
University of Southern California
Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver
National Cancer Institute (NCI)
Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery
Duke University
Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer
Barbara Ann Karmanos Cancer Institute
Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer
National Cancer Institute (NCI)
S0030: Capecitabine in Treating Older Patients W/Metastatic or Recurrent Colorectal Cancer That Cannot Be Surgically Removed
SWOG Cancer Research Network
S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer
SWOG Cancer Research Network
Capecitabine and Oxaliplatin With or Without Cetuximab in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
Swiss Cancer Institute
Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Neoadjuvant Radiation Therapy and Capecitabine in Treating Patients With Stage III or Stage IV Colorectal Adenocarcinoma
National Cancer Institute (NCI)
Irinotecan With or Without Capecitabine as Second-Line Therapy in Treating Older Patients With Progressive, Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)